Cocrystal Pharma, Inc. (COCP) 10-Year Financial Performance & Capital Metrics

COCP • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.Show more

Revenue $0
EBITDA -$18M +3.4%
Net Income -$18M +2.7%
EPS (Diluted) -1.72 -90426.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -97.5% -78.8%
ROIC -799.79% -32.3%
Debt/Equity 0.19 +170.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM48.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.19%

ROCE

10Y Avg-52.18%

5Y Avg-51.72%

3Y Avg-70.87%

Latest-91.62%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.35B	18.28	22.57	65.15%	42.87%	48.57%	2.53%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	86.21M	2.90	-0.23			-49.37%		0.24
INOInovio Pharmaceuticals, Inc.	112.67M	1.64	-0.42	-73.83%	-592.82%	-115.42%		0.17
ALGSAligos Therapeutics, Inc.	48.45M	9.05	-0.43	-74.6%	-32.68%	-120.37%
BRNSBarinthus Biotherapeutics plc	30.83M	0.76	-0.49	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.99M	1.16	-0.67			-126.11%		0.19
KLRSKalaris Therapeutics Inc	172.81M	9.24	-0.79			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	78K	0	0	0	6.56M	2.01M	0	0	0	0
Revenue Growth %	7.67%	-1%	-	-	-	-0.69%	-1%	-	-	-
Cost of Goods Sold+	192K	201K	101K	50K	4M	6.03M	8.79M	12.39M	15.17M	12.54M
COGS % of Revenue	2.46%	-	-	-	0.61%	3%	-	-	-	-
Gross Profit+	-114K	-201K	-101K	-50K	2.56M	-4.02M	-8.79M	-12.39M	-15.17M	-12.54M
Gross Margin %	-1.46%	-	-	-	0.39%	-2%	-	-	-	-
Gross Profit Growth %	-24.13%	-0.76%	0.5%	0.5%	52.2%	-2.57%	-1.19%	-0.41%	-0.22%	0.17%
Operating Expenses+	54.03M	105.82M	8.26M	62.92M	50.97M	5.57M	5.43M	26.44M	3.39M	5.34M
OpEx % of Revenue	692.64%	-	-	-	7.76%	2.76%	-	-	-	-
Selling, General & Admin	6.76M	4.14M	2.44M	4.35M	4.86M	5.57M	5.43M	5.75M	5.99M	5.34M
SG&A % of Revenue	86.73%	-	-	-	0.74%	2.76%	-	-	-	-
Research & Development	47.26M	101.68M	5.82M	58.57M	4M	6.03M	8.79M	12.39M	15.17M	12.54M
R&D % of Revenue	605.91%	-	-	-	0.61%	3%	-	-	-	-
Other Operating Expenses	0	-1K	-131K	0	42.1M	-6.03M	-8.79M	8.3M	-17.77M	-12.54M
Operating Income+	-53.95M	-105.82M	-8.26M	-62.92M	-48.41M	-9.59M	-14.22M	-38.83M	-18.56M	-17.88M
Operating Margin %	-691.64%	-	-	-	-7.37%	-4.76%	-	-	-	-
Operating Income Growth %	-8.3%	-0.96%	0.92%	-6.62%	0.23%	0.8%	-0.48%	-1.73%	0.52%	0.04%
EBITDA+	-53.76M	-105.62M	-8.16M	-62.87M	-48.31M	-9.43M	-14.03M	-38.64M	-18.37M	-17.75M
EBITDA Margin %	-689.18%	-	-	-	-7.36%	-4.68%	-	-	-	-
EBITDA Growth %	-8.6%	-0.96%	0.92%	-6.7%	0.23%	0.8%	-0.49%	-1.75%	0.52%	0.03%
D&A (Non-Cash Add-back)	192K	201K	101K	50K	98K	157K	190K	185K	189K	126K
EBIT	-53.95M	-105.82M	-7.49M	-62.57M	-2.3M	-9.59M	-14.22M	-18.14M	-21.16M	-17.88M
Net Interest Income+	180K	0	0	0	-19K	-8K	-4K	-2K	640K	537K
Interest Income	180K	126K	0	0	0	0	4	2	640K	537K
Interest Expense	0	0	0	0	19K	8K	4K	2K	0	0
Other Income/Expense	-11.42M	1.55M	769K	294K	237K	-62K	36K	-8K	575K	374K
Pretax Income+	-65.37M	-104.27M	-7.49M	-62.63M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Pretax Margin %	-838.08%	-	-	-	-7.34%	-4.79%	-	-	-	-
Income Tax+	-15.25M	-29.39M	-6.88M	-13.58M	0	0	0	0	0	0
Effective Tax Rate %	0.77%	0.72%	0.08%	0.78%	1%	1%	1%	1%	1%	1%
Net Income+	-50.12M	-74.87M	-613K	-49.05M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Net Margin %	-642.59%	-	-	-	-7.34%	-4.79%	-	-	-	-
Net Income Growth %	-505.28%	-0.49%	0.99%	-79.01%	0.02%	0.8%	-0.47%	-1.74%	0.54%	0.03%
Net Income (Continuing)	-50.12M	-74.87M	-613K	-49.05M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-28.60	-38.14	-0.30	-21.01	-15.78	-2.01	-1.85	-4.77	-0.00	-1.72
EPS Growth %	-97.62%	-0.33%	0.99%	-69.03%	0.25%	0.87%	0.08%	-1.58%	1%	-
EPS (Basic)	-28.60	-38.17	-0.30	-21.01	-15.78	-2.01	-1.85	-4.77	-0.00	-1.72
Diluted Shares Outstanding	1.75M	1.96M	2.01M	2.33M	3.05M	4.8M	7.69M	8.14M	9.65M	10.17M
Basic Shares Outstanding	1.75M	1.96M	2.01M	2.33M	3.05M	4.8M	7.69M	8.14M	9.65M	10.17M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.92M	5.47M	2.18M	2.94M	8.28M	34.02M	59.32M	40.18M	29.09M	11.58M
Cash & Short-Term Investments	9.28M	3.64M	748K	2.72M	7.42M	33.01M	58.7M	37.14M	26.35M	9.86M
Cash Only	9.28M	3.64M	748K	2.72M	7.42M	33.01M	58.7M	37.14M	26.35M	9.86M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	202K	1.31M	1.29M	0	644K	556K	0	716K	890K	1.22M
Days Sales Outstanding	945.26	-	-	-	35.81	100.76	-	-	-	-
Inventory	0	0	29K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	104.8	-	-	-	-	-	-	-
Other Current Assets	441K	517K	28K	29K	50K	50K	50K	2.32M	1.85M	505K
Total Non-Current Assets+	214.31M	119.41M	119.25M	65.62M	20.25M	20.23M	20.07M	662K	2.17M	1.88M
Property, Plant & Equipment	430K	280K	119K	384K	1.11M	1.09M	931K	616K	2.12M	1.85M
Fixed Asset Turnover	0.18x	-	-	-	5.92x	1.85x	-	-	-	-
Goodwill	65.19M	65.19M	65.19M	65.19M	19.09M	19.09M	19.09M	0	0	0
Intangible Assets	146.3M	53.91M	53.91M	0	0	0	0	0	0	0
Long-Term Investments	2.35M	-23.91M	31K	-19.78M	0	0	0	0	0	0
Other Non-Current Assets	-16.44M	31K	-293K	40K	50K	46K	46K	46K	46K	29K
Total Assets+	224.23M	124.88M	121.43M	68.56M	28.53M	54.24M	79.39M	40.84M	31.26M	13.46M
Asset Turnover	0.00x	-	-	-	0.23x	0.04x	-	-	-	-
Asset Growth %	-0.14%	-0.44%	-0.03%	-0.44%	-0.58%	0.9%	0.46%	-0.49%	-0.23%	-0.57%
Total Current Liabilities+	6.7M	2.04M	1.41M	1.56M	2.29M	1.36M	1.54M	1.22M	3.26M	2.43M
Accounts Payable	2.58M	563K	494K	616K	1.51M	657K	578K	614K	1.22M	1.54M
Days Payables Outstanding	4.91K	1.02K	1.79K	4.5K	137.74	39.74	23.99	18.09	29.4	44.89
Short-Term Debt	0	0	0	214K	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	464K	0	0	0	0	0	0
Other Current Liabilities	4.12M	1.48M	569K	127K	7K	187K	116K	130K	1.69M	0
Current Ratio	1.48x	2.68x	1.55x	1.89x	3.62x	25.05x	38.40x	33.04x	8.92x	4.77x
Quick Ratio	1.48x	2.68x	1.53x	1.89x	3.62x	25.05x	38.40x	33.04x	8.92x	4.77x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	49.94M	20.52M	14.62M	117K	537K	379K	298K	57K	1.61M	1.5M
Long-Term Debt	0	0	1.01M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	117K	537K	379K	298K	57K	1.61M	1.5M
Deferred Tax Liabilities	49.88M	20.46M	13.58M	19.78M	0	0	0	0	0	0
Other Non-Current Liabilities	61K	63K	0	0	0	0	0	0	0	0
Total Liabilities	56.64M	22.56M	16.03M	1.67M	2.82M	1.74M	1.84M	1.27M	4.88M	3.93M
Total Debt+	0	0	1.01M	331K	817K	596K	534K	297K	1.85M	1.81M
Net Debt	-9.28M	-3.64M	259K	-2.39M	-6.6M	-32.41M	-58.17M	-36.85M	-24.5M	-8.05M
Debt / Equity	-	-	0.01x	0.00x	0.03x	0.01x	0.01x	0.01x	0.07x	0.19x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-2547.68x	-1198.25x	-3555.25x	-19414.50x	-	-
Total Equity+	167.59M	102.32M	105.4M	66.89M	25.71M	52.51M	77.55M	39.57M	26.38M	9.52M
Equity Growth %	24.2%	-0.39%	0.03%	-0.37%	-0.62%	1.04%	0.48%	-0.49%	-0.33%	-0.64%
Book Value per Share	95.62	52.12	52.42	28.66	8.42	10.95	10.09	4.86	2.73	0.94
Total Shareholders' Equity	167.59M	102.32M	105.4M	66.89M	25.71M	52.51M	77.55M	39.57M	26.38M	9.52M
Common Stock	694K	714K	24K	30K	36K	71K	8K	8K	10K	10K
Retained Earnings	-62.56M	-137.43M	-138.04M	-187.09M	-235.26M	-244.91M	-259.09M	-297.93M	-315.91M	-333.42M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.15M	-1.35M	-1.36M	-983K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.32M	-14.65M	-6.9M	-8.29M	-1.56M	-9.83M	-12.72M	-21.43M	-14.67M	-16.48M
Operating CF Margin %	-132.27%	-	-	-	-0.24%	-4.88%	-	-	-	-
Operating CF Growth %	-0.72%	-0.42%	0.53%	-0.2%	0.81%	-5.29%	-0.29%	-0.69%	0.32%	-0.12%
Net Income	-50.12M	-74.87M	-613K	-49.05M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Depreciation & Amortization	192K	201K	101K	50K	98K	157K	190K	388K	-1.39M	126K
Stock-Based Compensation	2.93M	548K	614K	562K	351K	662K	724K	855K	801K	643K
Deferred Taxes	-15.27M	-29.41M	-6.88M	-13.58M	45.85M	54K	-49K	0	0	0
Other Non-Cash Items	50.27M	90.97M	-807K	53.61M	-133K	-177K	-195K	18.87M	1.56M	110K
Working Capital Changes	1.68M	-2.08M	682K	117K	443K	-878K	796K	-2.71M	2.34M	140K
Change in Receivables	0	11K	20K	0	-644K	88K	556K	-716K	0	-325K
Change in Inventory	0	0	0	0	-919K	919K	-217K	716K	0	0
Change in Payables	0	-2.02M	281K	0	919K	-919K	217K	-321K	2.05M	-895K
Cash from Investing+	-262K	3K	-40K	1.37M	-145K	-240K	-52K	-74K	-118K	-8K
Capital Expenditures	-339K	-51K	-40K	-28K	-145K	-240K	-52K	-74K	-118K	-8K
CapEx % of Revenue	4.35%	-	-	-	0.02%	0.12%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	77K	54K	0	1.4M	0	0	0	0	0	0
Cash from Financing+	15.88K	9.02K	4.08M	8.89M	6.42M	35.66M	38.47M	-27K	3.99M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	23K	3K	80K	228K	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.66M	-14.71M	-6.94M	-8.32M	-1.71M	-10.07M	-12.77M	-21.51M	-14.78M	-16.49M
FCF Margin %	-136.62%	-	-	-	-0.26%	-5%	-	-	-	-
FCF Growth %	-0.77%	-0.38%	0.53%	-0.2%	0.79%	-4.9%	-0.27%	-0.68%	0.31%	-0.12%
FCF per Share	-6.08	-7.49	-3.45	-3.56	-0.56	-2.10	-1.66	-2.64	-1.53	-1.62
FCF Conversion (FCF/Net Income)	0.21x	0.20x	11.26x	0.17x	0.03x	1.02x	0.90x	0.55x	0.82x	0.94x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.53%	-55.48%	-0.59%	-56.94%	-104.04%	-24.67%	-21.81%	-66.32%	-54.54%	-97.5%
Return on Invested Capital (ROIC)	-50.26%	-61.76%	-6.07%	-55.47%	-86.85%	-36.68%	-54.05%	-263.57%	-604.66%	-799.79%
Gross Margin	-146.15%	-	-	-	39%	-199.6%	-	-	-	-
Net Margin	-64258.97%	-	-	-	-733.84%	-479.05%	-	-	-	-
Debt / Equity	-	-	0.01x	0.00x	0.03x	0.01x	0.01x	0.01x	0.07x	0.19x
Interest Coverage	-	-	-	-	-2547.68x	-1198.25x	-3555.25x	-19414.50x	-	-
FCF Conversion	0.21x	0.20x	11.26x	0.17x	0.03x	1.02x	0.90x	0.55x	0.82x	0.94x
Revenue Growth	766.67%	-100%	-	-	-	-69.32%	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Cocrystal Pharma, Inc. (COCP) grew revenue by 0.0% over the past year. Growth has been modest.

Cocrystal Pharma, Inc. (COCP) reported a net loss of $9.7M for fiscal year 2024.

Dividend & Returns

Cocrystal Pharma, Inc. (COCP) has a return on equity (ROE) of -97.5%. Negative ROE indicates the company is unprofitable.

Cocrystal Pharma, Inc. (COCP) had negative free cash flow of $9.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cocrystal Pharma, Inc. (COCP) 10-Year Financial Performance & Capital Metrics

COCP • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $0
EBITDA -$18M +3.4%
Net Income -$18M +2.7%
EPS (Diluted) -1.72 -90426.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -97.5% -78.8%
ROIC -799.79% -32.3%
Debt/Equity 0.19 +170.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM48.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM49.19%

ROCE

10Y Avg-52.18%

5Y Avg-51.72%

3Y Avg-70.87%

Latest-91.62%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.35B	18.28	22.57	65.15%	42.87%	48.57%	2.53%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	86.21M	2.90	-0.23			-49.37%		0.24
INOInovio Pharmaceuticals, Inc.	112.67M	1.64	-0.42	-73.83%	-592.82%	-115.42%		0.17
ALGSAligos Therapeutics, Inc.	48.45M	9.05	-0.43	-74.6%	-32.68%	-120.37%
BRNSBarinthus Biotherapeutics plc	30.83M	0.76	-0.49	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.99M	1.16	-0.67			-126.11%		0.19
KLRSKalaris Therapeutics Inc	172.81M	9.24	-0.79			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	78K	0	0	0	6.56M	2.01M	0	0	0	0
Revenue Growth %	7.67%	-1%	-	-	-	-0.69%	-1%	-	-	-
Cost of Goods Sold+	192K	201K	101K	50K	4M	6.03M	8.79M	12.39M	15.17M	12.54M
COGS % of Revenue	2.46%	-	-	-	0.61%	3%	-	-	-	-
Gross Profit+	-114K	-201K	-101K	-50K	2.56M	-4.02M	-8.79M	-12.39M	-15.17M	-12.54M
Gross Margin %	-1.46%	-	-	-	0.39%	-2%	-	-	-	-
Gross Profit Growth %	-24.13%	-0.76%	0.5%	0.5%	52.2%	-2.57%	-1.19%	-0.41%	-0.22%	0.17%
Operating Expenses+	54.03M	105.82M	8.26M	62.92M	50.97M	5.57M	5.43M	26.44M	3.39M	5.34M
OpEx % of Revenue	692.64%	-	-	-	7.76%	2.76%	-	-	-	-
Selling, General & Admin	6.76M	4.14M	2.44M	4.35M	4.86M	5.57M	5.43M	5.75M	5.99M	5.34M
SG&A % of Revenue	86.73%	-	-	-	0.74%	2.76%	-	-	-	-
Research & Development	47.26M	101.68M	5.82M	58.57M	4M	6.03M	8.79M	12.39M	15.17M	12.54M
R&D % of Revenue	605.91%	-	-	-	0.61%	3%	-	-	-	-
Other Operating Expenses	0	-1K	-131K	0	42.1M	-6.03M	-8.79M	8.3M	-17.77M	-12.54M
Operating Income+	-53.95M	-105.82M	-8.26M	-62.92M	-48.41M	-9.59M	-14.22M	-38.83M	-18.56M	-17.88M
Operating Margin %	-691.64%	-	-	-	-7.37%	-4.76%	-	-	-	-
Operating Income Growth %	-8.3%	-0.96%	0.92%	-6.62%	0.23%	0.8%	-0.48%	-1.73%	0.52%	0.04%
EBITDA+	-53.76M	-105.62M	-8.16M	-62.87M	-48.31M	-9.43M	-14.03M	-38.64M	-18.37M	-17.75M
EBITDA Margin %	-689.18%	-	-	-	-7.36%	-4.68%	-	-	-	-
EBITDA Growth %	-8.6%	-0.96%	0.92%	-6.7%	0.23%	0.8%	-0.49%	-1.75%	0.52%	0.03%
D&A (Non-Cash Add-back)	192K	201K	101K	50K	98K	157K	190K	185K	189K	126K
EBIT	-53.95M	-105.82M	-7.49M	-62.57M	-2.3M	-9.59M	-14.22M	-18.14M	-21.16M	-17.88M
Net Interest Income+	180K	0	0	0	-19K	-8K	-4K	-2K	640K	537K
Interest Income	180K	126K	0	0	0	0	4	2	640K	537K
Interest Expense	0	0	0	0	19K	8K	4K	2K	0	0
Other Income/Expense	-11.42M	1.55M	769K	294K	237K	-62K	36K	-8K	575K	374K
Pretax Income+	-65.37M	-104.27M	-7.49M	-62.63M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Pretax Margin %	-838.08%	-	-	-	-7.34%	-4.79%	-	-	-	-
Income Tax+	-15.25M	-29.39M	-6.88M	-13.58M	0	0	0	0	0	0
Effective Tax Rate %	0.77%	0.72%	0.08%	0.78%	1%	1%	1%	1%	1%	1%
Net Income+	-50.12M	-74.87M	-613K	-49.05M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Net Margin %	-642.59%	-	-	-	-7.34%	-4.79%	-	-	-	-
Net Income Growth %	-505.28%	-0.49%	0.99%	-79.01%	0.02%	0.8%	-0.47%	-1.74%	0.54%	0.03%
Net Income (Continuing)	-50.12M	-74.87M	-613K	-49.05M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-28.60	-38.14	-0.30	-21.01	-15.78	-2.01	-1.85	-4.77	-0.00	-1.72
EPS Growth %	-97.62%	-0.33%	0.99%	-69.03%	0.25%	0.87%	0.08%	-1.58%	1%	-
EPS (Basic)	-28.60	-38.17	-0.30	-21.01	-15.78	-2.01	-1.85	-4.77	-0.00	-1.72
Diluted Shares Outstanding	1.75M	1.96M	2.01M	2.33M	3.05M	4.8M	7.69M	8.14M	9.65M	10.17M
Basic Shares Outstanding	1.75M	1.96M	2.01M	2.33M	3.05M	4.8M	7.69M	8.14M	9.65M	10.17M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.92M	5.47M	2.18M	2.94M	8.28M	34.02M	59.32M	40.18M	29.09M	11.58M
Cash & Short-Term Investments	9.28M	3.64M	748K	2.72M	7.42M	33.01M	58.7M	37.14M	26.35M	9.86M
Cash Only	9.28M	3.64M	748K	2.72M	7.42M	33.01M	58.7M	37.14M	26.35M	9.86M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	202K	1.31M	1.29M	0	644K	556K	0	716K	890K	1.22M
Days Sales Outstanding	945.26	-	-	-	35.81	100.76	-	-	-	-
Inventory	0	0	29K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	104.8	-	-	-	-	-	-	-
Other Current Assets	441K	517K	28K	29K	50K	50K	50K	2.32M	1.85M	505K
Total Non-Current Assets+	214.31M	119.41M	119.25M	65.62M	20.25M	20.23M	20.07M	662K	2.17M	1.88M
Property, Plant & Equipment	430K	280K	119K	384K	1.11M	1.09M	931K	616K	2.12M	1.85M
Fixed Asset Turnover	0.18x	-	-	-	5.92x	1.85x	-	-	-	-
Goodwill	65.19M	65.19M	65.19M	65.19M	19.09M	19.09M	19.09M	0	0	0
Intangible Assets	146.3M	53.91M	53.91M	0	0	0	0	0	0	0
Long-Term Investments	2.35M	-23.91M	31K	-19.78M	0	0	0	0	0	0
Other Non-Current Assets	-16.44M	31K	-293K	40K	50K	46K	46K	46K	46K	29K
Total Assets+	224.23M	124.88M	121.43M	68.56M	28.53M	54.24M	79.39M	40.84M	31.26M	13.46M
Asset Turnover	0.00x	-	-	-	0.23x	0.04x	-	-	-	-
Asset Growth %	-0.14%	-0.44%	-0.03%	-0.44%	-0.58%	0.9%	0.46%	-0.49%	-0.23%	-0.57%
Total Current Liabilities+	6.7M	2.04M	1.41M	1.56M	2.29M	1.36M	1.54M	1.22M	3.26M	2.43M
Accounts Payable	2.58M	563K	494K	616K	1.51M	657K	578K	614K	1.22M	1.54M
Days Payables Outstanding	4.91K	1.02K	1.79K	4.5K	137.74	39.74	23.99	18.09	29.4	44.89
Short-Term Debt	0	0	0	214K	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	464K	0	0	0	0	0	0
Other Current Liabilities	4.12M	1.48M	569K	127K	7K	187K	116K	130K	1.69M	0
Current Ratio	1.48x	2.68x	1.55x	1.89x	3.62x	25.05x	38.40x	33.04x	8.92x	4.77x
Quick Ratio	1.48x	2.68x	1.53x	1.89x	3.62x	25.05x	38.40x	33.04x	8.92x	4.77x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	49.94M	20.52M	14.62M	117K	537K	379K	298K	57K	1.61M	1.5M
Long-Term Debt	0	0	1.01M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	117K	537K	379K	298K	57K	1.61M	1.5M
Deferred Tax Liabilities	49.88M	20.46M	13.58M	19.78M	0	0	0	0	0	0
Other Non-Current Liabilities	61K	63K	0	0	0	0	0	0	0	0
Total Liabilities	56.64M	22.56M	16.03M	1.67M	2.82M	1.74M	1.84M	1.27M	4.88M	3.93M
Total Debt+	0	0	1.01M	331K	817K	596K	534K	297K	1.85M	1.81M
Net Debt	-9.28M	-3.64M	259K	-2.39M	-6.6M	-32.41M	-58.17M	-36.85M	-24.5M	-8.05M
Debt / Equity	-	-	0.01x	0.00x	0.03x	0.01x	0.01x	0.01x	0.07x	0.19x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-2547.68x	-1198.25x	-3555.25x	-19414.50x	-	-
Total Equity+	167.59M	102.32M	105.4M	66.89M	25.71M	52.51M	77.55M	39.57M	26.38M	9.52M
Equity Growth %	24.2%	-0.39%	0.03%	-0.37%	-0.62%	1.04%	0.48%	-0.49%	-0.33%	-0.64%
Book Value per Share	95.62	52.12	52.42	28.66	8.42	10.95	10.09	4.86	2.73	0.94
Total Shareholders' Equity	167.59M	102.32M	105.4M	66.89M	25.71M	52.51M	77.55M	39.57M	26.38M	9.52M
Common Stock	694K	714K	24K	30K	36K	71K	8K	8K	10K	10K
Retained Earnings	-62.56M	-137.43M	-138.04M	-187.09M	-235.26M	-244.91M	-259.09M	-297.93M	-315.91M	-333.42M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.15M	-1.35M	-1.36M	-983K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.32M	-14.65M	-6.9M	-8.29M	-1.56M	-9.83M	-12.72M	-21.43M	-14.67M	-16.48M
Operating CF Margin %	-132.27%	-	-	-	-0.24%	-4.88%	-	-	-	-
Operating CF Growth %	-0.72%	-0.42%	0.53%	-0.2%	0.81%	-5.29%	-0.29%	-0.69%	0.32%	-0.12%
Net Income	-50.12M	-74.87M	-613K	-49.05M	-48.17M	-9.65M	-14.19M	-38.84M	-17.98M	-17.5M
Depreciation & Amortization	192K	201K	101K	50K	98K	157K	190K	388K	-1.39M	126K
Stock-Based Compensation	2.93M	548K	614K	562K	351K	662K	724K	855K	801K	643K
Deferred Taxes	-15.27M	-29.41M	-6.88M	-13.58M	45.85M	54K	-49K	0	0	0
Other Non-Cash Items	50.27M	90.97M	-807K	53.61M	-133K	-177K	-195K	18.87M	1.56M	110K
Working Capital Changes	1.68M	-2.08M	682K	117K	443K	-878K	796K	-2.71M	2.34M	140K
Change in Receivables	0	11K	20K	0	-644K	88K	556K	-716K	0	-325K
Change in Inventory	0	0	0	0	-919K	919K	-217K	716K	0	0
Change in Payables	0	-2.02M	281K	0	919K	-919K	217K	-321K	2.05M	-895K
Cash from Investing+	-262K	3K	-40K	1.37M	-145K	-240K	-52K	-74K	-118K	-8K
Capital Expenditures	-339K	-51K	-40K	-28K	-145K	-240K	-52K	-74K	-118K	-8K
CapEx % of Revenue	4.35%	-	-	-	0.02%	0.12%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	77K	54K	0	1.4M	0	0	0	0	0	0
Cash from Financing+	15.88K	9.02K	4.08M	8.89M	6.42M	35.66M	38.47M	-27K	3.99M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	23K	3K	80K	228K	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.66M	-14.71M	-6.94M	-8.32M	-1.71M	-10.07M	-12.77M	-21.51M	-14.78M	-16.49M
FCF Margin %	-136.62%	-	-	-	-0.26%	-5%	-	-	-	-
FCF Growth %	-0.77%	-0.38%	0.53%	-0.2%	0.79%	-4.9%	-0.27%	-0.68%	0.31%	-0.12%
FCF per Share	-6.08	-7.49	-3.45	-3.56	-0.56	-2.10	-1.66	-2.64	-1.53	-1.62
FCF Conversion (FCF/Net Income)	0.21x	0.20x	11.26x	0.17x	0.03x	1.02x	0.90x	0.55x	0.82x	0.94x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.53%	-55.48%	-0.59%	-56.94%	-104.04%	-24.67%	-21.81%	-66.32%	-54.54%	-97.5%
Return on Invested Capital (ROIC)	-50.26%	-61.76%	-6.07%	-55.47%	-86.85%	-36.68%	-54.05%	-263.57%	-604.66%	-799.79%
Gross Margin	-146.15%	-	-	-	39%	-199.6%	-	-	-	-
Net Margin	-64258.97%	-	-	-	-733.84%	-479.05%	-	-	-	-
Debt / Equity	-	-	0.01x	0.00x	0.03x	0.01x	0.01x	0.01x	0.07x	0.19x
Interest Coverage	-	-	-	-	-2547.68x	-1198.25x	-3555.25x	-19414.50x	-	-
FCF Conversion	0.21x	0.20x	11.26x	0.17x	0.03x	1.02x	0.90x	0.55x	0.82x	0.94x
Revenue Growth	766.67%	-100%	-	-	-	-69.32%	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

Cocrystal Pharma, Inc. (COCP) grew revenue by 0.0% over the past year. Growth has been modest.

Cocrystal Pharma, Inc. (COCP) reported a net loss of $9.7M for fiscal year 2024.

Dividend & Returns

Cocrystal Pharma, Inc. (COCP) has a return on equity (ROE) of -97.5%. Negative ROE indicates the company is unprofitable.

Cocrystal Pharma, Inc. (COCP) had negative free cash flow of $9.8M in fiscal year 2024, likely due to heavy capital investments.